Epidermal growth factor receptor (EGFR) is overexpressed by several solid tumors,
including pancreatic cancer, and has become an important target for novel anticancer …

Objective Erlotinib plus gemcitabine is approved in Japan for the treatment of metastatic
pancreatic cancer. The POLARIS surveillance study investigated safety (focusing on …

Abstract On November 18, 2004, erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville,
NY, http://www. osip. com, and Genentech, Inc., South San Francisco, CA, http://www. gene …

Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the
epidermal growth factor receptor. Randomized, controlled clinical studies have …

Background Rash, liver dysfunction, and diarrhea are known major adverse events
associated with erlotinib and gefitinib. However, clinical trials with gefitinib have reported …

Purpose The purpose of this phase IB trial was to evaluate the tolerability, pharmacokinetics
and preliminary evidence of antitumor activity of erlotinib plus gemcitabine in patients with …

Abstract Treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase
inhibitor used for treating non-small-cell lung cancer (NSCLC) and other cancers, is …

Objectives An association between skin toxicity and outcome has been reported for NSCLC
patients treated with erlotinib. Several explanations have been suggested, including …

With the increased use of tyrosine kinase inhibitors as successful therapy in selected
malignancies, their adverse effects will grow, especially when combination therapy is used …

Purpose Epidermal growth factor receptor/human epidermal growth factor receptor 1
(EGFR/HER1) and ligand expression is frequently seen in hepatocellular cancers (HCCs) …